{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,9,2]],"date-time":"2023-09-02T12:34:59Z","timestamp":1693658099478},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"5_Supplement_1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2016,3,1]]},"DOI":"10.2146\/sp150031","type":"journal-article","created":{"date-parts":[[2016,2,19]],"date-time":"2016-02-19T11:15:20Z","timestamp":1455880520000},"page":"S35-S41","source":"Crossref","is-referenced-by-count":3,"title":["Medication utilization evaluation of dabigatran and rivaroxaban within a large, multi-center health system"],"prefix":"10.1093","volume":"73","author":[{"given":"Alex N.","family":"Isaacs","sequence":"first","affiliation":[{"name":"Indiana University Health, Indianapolis, IN"},{"name":"Butler University College of Pharmacy and Health Sciences, Indianapolis, IN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meagan","family":"Doolin","sequence":"additional","affiliation":[{"name":"Butler University College of Pharmacy and Health Sciences, Indianapolis, IN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Courtney","family":"Morse","sequence":"additional","affiliation":[{"name":"Butler University College of Pharmacy and Health Sciences, Indianapolis, IN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erin","family":"Shiltz","sequence":"additional","affiliation":[{"name":"Clinical Pharmacy Specialist\u2013Internal Medicine, Indiana University Health, Indianapolis, IN"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah A.","family":"Nisly","sequence":"additional","affiliation":[{"name":"Butler University College of Pharmacy and Health Sciences, Indianapolis, IN"},{"name":"Clinical Pharmacy Specialist\u2013Internal Medicine, Indiana University Health, Indianapolis, IN"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","reference":[{"key":"key\n\t\t\t\t2019041102213594500_b1-0730s35","volume-title":"Pradaxa\u00ae [package insert]","year":"2012"},{"key":"key\n\t\t\t\t2019041102213594500_b2-0730s35","volume-title":"Xarelto\u00ae [package insert]","year":"2012"},{"key":"key\n\t\t\t\t2019041102213594500_b3-0730s35","unstructured":"FDA expands use of Xarelto to treat, reduce recurrence of blood clots. Food and Drug Administration Website. http:\/\/www.fda.gov\/NewsEvents\/Newsroom\/PressAnnouncements\/ucm326654.htm. Nov2012 (accessed 2013 May 6)."},{"issue":"12","key":"key\n\t\t\t\t2019041102213594500_b4-0730s35","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041102213594500_b5-0730s35","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041102213594500_b6-0730s35","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1056\/NEJMoa0800374","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty","volume":"358","author":"Eriksson","year":"2008","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041102213594500_b7-0730s35","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)60880-6","article-title":"Extended duration rivaroxaban versus short-term enoxparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial","volume":"372","author":"Kakkar","year":"2008","journal-title":"Lancet"},{"key":"key\n\t\t\t\t2019041102213594500_b8-0730s35","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1056\/NEJMoa076016","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after knee arthroplasty","volume":"358","author":"Lassen","year":"2008","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t2019041102213594500_b9-0730s35","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/S0140-6736(09)60734-0","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty","volume":"373","author":"Turpie","year":"2009","journal-title":"Lancet"},{"issue":"26","key":"key\n\t\t\t\t2019041102213594500_b10-0730s35","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1056\/NEJMoa1007903","article-title":"Oral rivaroxaban for symptomatic venous thromboembolism","volume":"363","author":"Bauersachs","year":"2010","journal-title":"NEJM"},{"issue":"14","key":"key\n\t\t\t\t2019041102213594500_b11-0730s35","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1056\/NEJMoa1113572","article-title":"Oral rivaroxaban for symptomatic pulmonary embolism","volume":"366","author":"Bauersachs","year":"2012","journal-title":"NEJM"},{"key":"key\n\t\t\t\t2019041102213594500_b12-0730s35","unstructured":"FDA drug safety communication: safety review of post- market reports of serious bleeding events with anticoagulant Pradaxa. Food and Drug Administration Website. www.fda.gov\/Drugs\/DrugSafety\/ucm282724.htm#data. Dec2011 (accessed 2013 May 6)."},{"key":"key\n\t\t\t\t2019041102213594500_b13-0730s35","unstructured":"Drug report: Xarelto. Adverse Events Website. http:\/\/www.adverseevents.com\/drugdetail.php?AEDrugID=5158&BrandName=XARELTO&AEMode=HLT. Aug2012 (accessed 2013 May 6)."},{"key":"key\n\t\t\t\t2019041102213594500_b14-0730s35","unstructured":"National patient safety goals NPSG 03.05.01. The Joint Commission Website. www.jointcommission.org\/assets\/1\/18\/NPSG_Chapter_Jan2013_HAP.pdf. Jan2013 (accessed 2013 May 6)"},{"key":"key\n\t\t\t\t2019041102213594500_b15-0730s35","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1345\/aph.1R634","article-title":"Delivery of optimized inpatient anticoagulation therapy: consensus statement from the Anticoagulation Forum","volume":"47","author":"Nutescu","year":"2013","journal-title":"Ann Pharmacother"}],"container-title":["American Journal of Health-System Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ajhp\/article-pdf\/73\/5_Supplement_1\/S35\/28335094\/ajhp0s35.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,9,4]],"date-time":"2019-09-04T19:31:39Z","timestamp":1567625499000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ajhp\/article\/73\/5_Supplement_1\/S35\/5101727"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,1]]},"references-count":15,"journal-issue":{"issue":"5_Supplement_1","published-print":{"date-parts":[[2016,3,1]]}},"URL":"https:\/\/doi.org\/10.2146\/sp150031","relation":{},"ISSN":["1079-2082","1535-2900"],"issn-type":[{"value":"1079-2082","type":"print"},{"value":"1535-2900","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2016,3,1]]},"published":{"date-parts":[[2016,3,1]]}}}